

S4 Table. Patient characteristics and outcomes of first-line chemotherapy with single regimen

Clinical characteristic	Single (n=772)	Fluoropyrimidine recurrent (n=203, 26.3%)	for Fluoropyrimidine metastatic (n=351, 45.5%)	for Taxane for recurrent (n=218, 28.2%)	p-value
Male sex	529 (68.5)	147 (72.4)	229 (65.2)	153 (70.2)	0.178
Age ≥ 65 yr	4,736 (61.7)	142 (70.0)	282 (80.3)	52 (23.9)	<0.001
ECOG PS					<0.001
0/1	640 (82.9)	166 (81.8)	275 (78.3)	199 (91.3)	
2/3	132 (17.1)	37 (18.2)	76 (21.7)	19 (8.7)	
No. of metastasis, 2 or more	232 (30.2)	46 (22.8)	118 (33.6)	68 (31.5)	0.025
Prognostic score					< 0.001
0-1 (good)	307 (48.0)	136 (67.0)	86 (24.5)	149 (68.3)	
2-3 (moderate)	283 (36.7)	45 (22.2)	187 (53.3)	51 (23.4)	
4 or more (poor)	118 (15.3)	22 (10.8)	78 (22.2)	18 (8.3)	
Second-line chemotherapy, received	300 (38.9)	69 (34.0)	127 (36.2)	104 (47.7)	0.006
OS, Median (months, 95% CI)	8.7 (8.0-9.4)	10.6 (9.2-12.0)	7.9 (7.0-8.8)	8.7 (7.7-9.7)	< 0.001
PFS, Median (months, 95% CI)	4.2 (3.8-4.6)	5.4 (4.0-6.8)	4.4 (3.7-5.1)	3.9 (3.7-4.2)	0.004

Values are presented as number (%). CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; OS, overall survival; PFS, progression-free survival.